Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 2, 2013, Pages 232-238

  Palazzo, Maxime ^a,b   Lombard Bohas, Catherine ^d   Cadiot, Guillaume ^e   Matysiak Budnik, Tamara ^f   Rebours, Vinciane ^a,b   Vullierme, Marie Pierre ^a,b   Couvelard, Anne ^b,c   Hentic, Olivia ^a,b   Ruszniewski, Philippe ^a,b  

^a BEAUJON HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICHAT HOSPITAL   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e SERVICE DE DERMATOLOGIE   (France)

^f HÔTEL DIEU   (France)

Author keywords

Antiproliferative treatment; Lanreotide; Neuroendocrine tumors; Predictive factors; Somatostatin analog

Indexed keywords

ANGIOPEPTIN; KI 67 ANTIGEN; SOMATOSTATIN RECEPTOR; TUMOR MARKER;

ABDOMINAL PAIN; ADULT; AGE DISTRIBUTION; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER LOCALIZATION; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CELL ASSAY; COMMON BILE DUCT STONE; DIARRHEA; DIGESTIVE SYSTEM TUMOR; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; KI67 PROLIFERATION INDEX; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT DIGESTIVE NEUROENDOCRINE TUMOR; NEUROENDOCRINE TUMOR; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SCINTIGRAPHY; SEX DIFFERENCE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DIGESTIVE SYSTEM NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PEPTIDES, CYCLIC; PROGNOSIS; RETROSPECTIVE STUDIES; SOMATOSTATIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR BURDEN; YOUNG ADULT;

EID: 84872054168     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328359d1a6     Document Type: Article

References (44)

1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after 'carcinoid': Epidemiology of and prognostic factors for neuroendocrine tumors in 35 825 cases in the United States. J Clin Oncol 2008; 26:3063-3072
2. Lepage C, Rachet B, Coleman MP. Survival from malignant digestive endocrine tumors in England and Wales: A population-based study. Gastroenterology 2007; 132:899-904 (Pubitemid 46440869)
3. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997; 79:813-829 (Pubitemid 27076348)
4. Ohrvall U, Eriksson B, Juhlin C, Karacagil S, Rastad J, Hellman P, et al. Method for dissection of mesenteric metastases in mid-gut carcinoid tumors. World J Surg 2000; 24:1402-1408
5. Nave H, Mossinger E, Feist H, Lang H, Raab H. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: A retrospective, unicentric study over 13 years. Surgery 2001; 129:170-175
6. Hellman P, Lundstrom T, Ohrvall U, Eriksson B, Skogseid B, Oberg K, et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 2002; 26:991-997 (Pubitemid 36920298)
7. Norton JA,Warren RS, Kelly MG, Zuraek MB, Jensen RT. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003; 134:1057-1063, discussion 63-65
8. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: A plea for resection to increase survival. J Am Coll Surg 2003; 197: 29-37 (Pubitemid 36759176)
9. King J, Quinn R, Glenn DM, Janssen J, Tong D, Liaw W, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008; 113:921-929
10. Eriksson BK, Larsson EG, Skogseid BM, Lofberg AM, Lorelius LE, Oberg KE. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998; 83:2293-2301 (Pubitemid 28533498)
11. Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: Variables affecting response rates and survival. Cancer 2005; 104:1590-1602 (Pubitemid 41437421)
12. Ruszniewski P, Rougier P, Roche A, Legmann P, Sibert A, Hochlaf S, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993; 71:2624-2630 (Pubitemid 23100501)
13. Eriksson J, Stalberg P, Nilsson A, Krause J, Lundberg C, Skogseid B, et al. Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg 2008; 32:930-938
14. Cao CQ, Yan TD, Bester L, Liauw W, Morris DL. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 2010; 97:537-543
15. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocindoxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326:519-523
16. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004; 22:4762-4771
17. Jacobsen MB, Hanssen LE, Kolmannskog F, Schrumpf E,Vatn MH, Bergan A. Interferon-Alpha 2b, with or without prior hepatic artery embolization: Clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study. Scand J Gastroenterol 1995; 30:789-796
18. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: A random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008; 26: 1316-1323
19. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:514-523
20. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:501-513
21. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 2008; 26:2124-2130
22. Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15:966-973 (Pubitemid 39004355)
23. Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 2010; 16:2963-2970
24. Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB,Van Cutsem EJ, Fiasse RH, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 1999; 17:1111-1117 (Pubitemid 29162933)
25. Arnold R, Benning R, Neuhaus C, Rolwage M, Trautmann ME. Gastroenteropancreatic endocrine tumors: Effect of Sandostatin on tumor growth. The German Sandostatin Study Group. Metabolism 1992; 41 (SUPPL2):116-118
26. Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D, Tao Y, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993; 72:244-248 (Pubitemid 23182080)
27. Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, Michel H, et al. The antitumoral effect of the long-Acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000; 95:3276-3281
28. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 2009; 27:4656-4663
29. Hamilton SRALAE. World Health Organization Classification of Tumours. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000. p. 2000
30. DeLellis RALRV, Heitz PU, Eng C. World Health Organization Classification of Tumours. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press; 2004. p. 2004
31. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247
32. Arnold R, Wilke A, Rinke A, Mayer C, Kann PH, Klose KJ, et al. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 2008; 6: 820-827
33. Butturini G, Bettini R, Missiaglia E, Mantovani W, Dalai I, Capelli P, et al. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer 2006; 13:1213-1221 (Pubitemid 46212575)
34. Aparicio T, Ducreux M, Baudin E, Sabourin JC, De Baere T, Mitry E, et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001; 37:1014-1019 (Pubitemid 32397687)
35. Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A, et al. Prospective study of the antitumor efficacy of long-Term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 2002; 94: 331-343 (Pubitemid 34081361)
36. Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - The International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21: 2689-2696 (Pubitemid 46606312)
37. Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, et al. Prognostic factors and survival in endocrine tumor patients: Comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005; 12:1083-1092 (Pubitemid 41815799)
38. Dromain C, de Baere T, Lumbroso J, Caillet H, Laplanche A, Boige V, et al. Detection of liver metastases from endocrine tumors: A prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 2005; 23:70-78 (Pubitemid 41702624)
39. Cheema A, Weber J, Strosberg Jr. Incidental detection of pancreatic neuroendocrine tumors: An analysis of incidence and outcomes. Ann Surg Oncol 2012;2932-2936
40. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: Does resection prolong survival? J Am Coll Surg 1998; 187:88-92, discussion-3
41. Musunuru S, Chen H, Rajpal S, Stephani N, McDermott JC, Holen K, et al. Metastatic neuroendocrine hepatic tumors: Resection improves survival. Arch Surg. 2006; 141:1000-1004, discussion 5 (Pubitemid 44583257)
42. Scigliano S, Lebtahi R, Maire F, Stievenart JL, Kianmanesh R, Sauvanet A, et al. Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: A 15-year monocentric experience. Endocr Relat Cancer 2009; 16:977-990
43. Elias D, Lefevre JH, Duvillard P, Goere D, Dromain C, Dumont F, et al. Hepatic metastases from neuroendocrine tumors with a 'thin slice' pathological examination: They are many more than you think. Ann Surg 2010; 251:307-310
44. IPSEN. Study of lanreotide autogel in non-functioning entero-pancreatic endocrine tumours (CLARINET), NCT00353496. Available at: Http:// clinicaltrials.gov/ct2/show/NCT00353496 [Accessed 29 August 2012